Literature DB >> 22230572

Practical theoretic guidance for the design of tumor-targeting agents.

K Dane Wittrup1, Greg M Thurber, Michael M Schmidt, John J Rhoden.   

Abstract

Theoretical analyses of targeting agent pharmacokinetics provides specific guidance with respect to desirable design objectives such as agent size, affinity, and target antigen. These analyses suggest that IgG-sized macromolecular constructs exhibit the most favorable balance between systemic clearance and vascular extravasation, resulting in maximal tumor uptake. Quantitative predictions of the effects of dose and binding affinity on tumor uptake and penetration are also provided. The single bolus dose required for saturation of xenografted tumors in mice can be predicted from knowledge of antigen expression level and metabolic half-life. The role of high binding affinity in tumor uptake can be summarized as: essential for small peptides, less important for antibodies, and negligible for nanoparticles.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230572      PMCID: PMC3978464          DOI: 10.1016/B978-0-12-396962-0.00010-0

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  35 in total

1.  Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

Authors:  Christilyn P Graff; K Dane Wittrup
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

2.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

Authors:  K J Harrington; S Mohammadtaghi; P S Uster; D Glass; A M Peters; R G Vile; J S Stewart
Journal:  Clin Cancer Res       Date:  2001-02       Impact factor: 12.531

3.  Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.

Authors:  Peter M Smith-Jones; Shankar Vallabhajosula; Vincent Navarro; Diego Bastidas; Stanley J Goldsmith; Neil H Bander
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

4.  Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice.

Authors:  M H Goldrosen; W C Biddle; J Pancook; S Bakshi; J L Vanderheyden; A R Fritzberg; A C Morgan; K A Foon
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

5.  Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.

Authors:  Stephen I Rudnick; Jianlong Lou; Calvin C Shaller; Yong Tang; Andres J P Klein-Szanto; Louis M Weiner; James D Marks; Gregory P Adams
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

6.  Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells.

Authors:  M J Mattes; G L Griffiths; H Diril; D M Goldenberg; G L Ong; L B Shih
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

7.  The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study.

Authors:  R D Blumenthal; I Fand; R M Sharkey; O C Boerman; R Kashi; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Preclinical characterisation of 111In-DTPA-trastuzumab.

Authors:  Marjolijn N Lub-de Hooge; Jos G W Kosterink; Patrick J Perik; Hugo Nijnuis; Ly Tran; Joost Bart; Albert J H Suurmeijer; Steven de Jong; Pieter L Jager; Elisabeth G E de Vries
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

9.  In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.

Authors:  Alberto Gabizon; Aviva T Horowitz; Dorit Goren; Dina Tzemach; Hilary Shmeeda; Samuel Zalipsky
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

10.  Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.

Authors:  K Fujimori; D G Covell; J E Fletcher; J N Weinstein
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701

View more
  69 in total

1.  Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.

Authors:  Andreas Lehmann; Josephine H F Wixted; Maxim V Shapovalov; Heinrich Roder; Roland L Dunbrack; Matthew K Robinson
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

2.  Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.

Authors:  Qi Zhao; Mahiuddin Ahmed; Hong-fen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  J Biol Chem       Date:  2015-04-07       Impact factor: 5.157

3.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer.

Authors:  Eben L Rosenthal; Jason M Warram; Esther de Boer; Thomas K Chung; Melissa L Korb; Margie Brandwein-Gensler; Theresa V Strong; Cecelia E Schmalbach; Anthony B Morlandt; Garima Agarwal; Yolanda E Hartman; William R Carroll; Joshua S Richman; Lisa K Clemons; Lisle M Nabell; Kurt R Zinn
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

Review 4.  The Immunoimaging Toolbox.

Authors:  Aaron T Mayer; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2018-05-24       Impact factor: 10.057

Review 5.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

6.  Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

Authors:  Alice Tzeng; Byron H Kwan; Cary F Opel; Tejas Navaratna; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

Review 7.  Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.

Authors:  Xin Xu; Yulia Vugmeyster
Journal:  AAPS J       Date:  2012-08-04       Impact factor: 4.009

8.  Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.

Authors:  Patty Wong; Lin Li; Junie Chea; Melissa K Delgado; Erasmus Poku; Barbara Szpikowska; Nicole Bowles; Megan Minnix; David Colcher; Jeffrey Y C Wong; John E Shively; Paul J Yazaki
Journal:  Cancer Biother Radiopharm       Date:  2017-09       Impact factor: 3.099

9.  Directed Evolution to Engineer Monobody for FRET Biosensor Assembly and Imaging at Live-Cell Surface.

Authors:  Praopim Limsakul; Qin Peng; Yiqian Wu; Molly E Allen; Jing Liang; Albert G Remacle; Tyler Lopez; Xin Ge; Brian K Kay; Huimin Zhao; Alex Y Strongin; Xiang-Lei Yang; Shaoying Lu; Yingxiao Wang
Journal:  Cell Chem Biol       Date:  2018-01-27       Impact factor: 8.116

10.  Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Authors:  Sarah M Cheal; Hong Xu; Hong-Fen Guo; Sang-Gyu Lee; Blesida Punzalan; Sandhya Chalasani; Edward K Fung; Achim Jungbluth; Pat B Zanzonico; Jorge A Carrasquillo; Joseph O'Donoghue; Peter M Smith-Jones; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.